A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment.
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 06 Dec 2016 New trial record